Sodium-glucose co-transporter-2 (SGLT2) inhibitors are relatively new class of antihyperglycemic medication that is well established in the management of type 2 diabetes mellitus (DM)1. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.